Fig. 2: APOA2 is responsible for acquired resistance to AAD in HCC-bearing mouse model. | Cell Death Discovery

Fig. 2: APOA2 is responsible for acquired resistance to AAD in HCC-bearing mouse model.

From: APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-β

Fig. 2: APOA2 is responsible for acquired resistance to AAD in HCC-bearing mouse model.

After the evaluation of acquired drug resistance, the HCC-bearing mice were divided into 3 groups: (C)control (n = 7), (R)resistant (n = 7), and (S)sensitive (n = 24). a Quantification of subcutaneous tumor mass and volume in the three groups. Numbers 1–7 represent control group, 1–7 for resistance group, and 1–7 for sensitivity group. *p < 0.05, ns, not significant. b. Representative images of CD31 immunofluorescence staining of tumor tissue. The upper part of the image is a comprehensive view of CD31 staining of the entire tumor tissue section, while the bottom part shows CD31 staining under magnification. CD31+ microvessel signals were randomly quantified from 12 fields (n = 7 mice in each group), Scale bars, 50 µm. *p < 0.05, ns, not significant. c and d. Western blotting of APOA2, VEGFR2, and P-VEGFR2 in tumor tissue (n = 4). e Representative images of APOA2 IHC staining intensity of tumor tissue, Scale bars, 100 µm. The upper part of the image is a comprehensive view of APOA2 staining of the entire tumor tissue section, while the bottom part shows APOA2 staining under magnification. Scale bars, 100 µm. *p < 0.05, ns, not significant.

Back to article page